medscape.com
Refractory Crohn's Disease: Effective Therapy by Inhibition of Interleukin 12 and Interleukin 23
This article reports positive trial results for ustekinumab, a drug that targets IL-12 and IL-23, showing benefit in people with Crohn's disease who did not respond to anti‑TNF drugs. That could expand options for patients with refractory disease.
Adults with moderate to severe Crohn's disease, especially those who have failed anti‑TNF therapy; clinicians who treat IBD; researchers studying cytokine-targeted therapies.
What To Know
Researchers tested ustekinumab — a monoclonal antibody that inhibits IL-12 and IL-23 — as induction and maintenance therapy for adults with moderate to severe Crohn's disease who were resistant to anti-TNF treatment.
In a randomized study of 526 patients, intravenous ustekinumab produced higher rates of clinical response at 6 weeks than placebo for the higher-dose group, and patients who responded to induction and continued ustekinumab maintenance injections had higher response and remission rates at 22 weeks.
The article summarizes trial design (IV induction at multiple doses, then subcutaneous 90 mg maintenance for responders) and highlights that ustekinumab was previously approved for psoriasis. It reports comparative response/remission percentages and notes significance without giving extensive trial methodology or safety details.
This appears to be a clinical trial report relevant to patients who have failed anti-TNF therapy. It is informational and not treatment advice; decisions about changing therapy should be made with a clinician.
The report summarizes randomized trial results (induction and maintenance phases) but does not provide full safety data or long-term outcomes. Ustekinumab had prior FDA approval for psoriasis; readers should consult full trial publications and clinical guidelines before considering treatment implications.
